Advertisement

Psychopharmaka

  • Martin J. Lohse
  • Anna Lorenzen
  • Bruno Müller-Oerlinghausen

Zusammenfassung

Die Verordnungsstruktur der Psychopharmaka hat sich in den letzten 10 Jahren auffällig verändert. Die Verordnungen der früher führenden Tranquillantien haben sich fast halbiert. Umgekehrt haben sich die Antidepressivaverordnungen seit 1992 annähernd verdoppelt. Dieser Trend setzte sich 2001 durch die Anstiege selektiver Antidepressiva fort. Demgegenüber haben sich Neuroleptika auf fast konstantem Niveau gehalten. Hier sind atypische Neuroleptika mit verbesserter Wirkung auf schizophrene Negativsymptome und geringerer Störung der Motorik wichtiger geworden, während klassische Neuroleptika weniger eingesetzt werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneimittelkommission der deutschen Apotheker (2002): BfArM-Bescheid zu Kava-Kava. Pharm. Ztg. 147: 6–7.Google Scholar
  2. Arzneimittelkommission der deutschen Ärzteschaft (Hrsg.) (1997): Empfehlungen zur Therapie der Depression. 1. Aufl. Sonderheft Arzneiverordnung in der Praxis. September 1997.Google Scholar
  3. Arzneimittelkommission der deutschen Ärzteschaft (Hrsg.) (2000): Empfehlungen zur Therapie von Angst-und Zwangsstörungen. 1. Aufl. Sonderheft Arzneiverordnung in der Praxis.Google Scholar
  4. Arzneimittelkommission der deutschen Ärzteschaft (2002): Olanzapin: hyperosmolares Coma diabeticum, Rhabdomyolyse, Niereninsuffizienz. Dtsch. Ärztebl. 99: A741.Google Scholar
  5. Baptista T., Lacruz A., Angeles F., Silvera R., de Mendoza S., Mendoza M.T. et al. (2001): Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 34: 223–231.PubMedCrossRefGoogle Scholar
  6. Barbenel D.M., Yusufi B., O’Shea D., Bench C.J. (2000): Mania in a patient receiving testosterone replacement postorchidectomy taking St John’s wort and sertraline. J. Psychopharmacol. 14: 84–86.PubMedCrossRefGoogle Scholar
  7. Barbui C., Hotopf M. (2001): Amitriptyline vs. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Brit. J. Psychiatry 178: 129–144.Google Scholar
  8. Barbui C., Hotopf M., Freemantle N., Boynton J., Churchill R., Eccles M.P. et al. (2000): Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst. Rev. 2000 (4): CD002791.Google Scholar
  9. Bauer M., Dopfner S. (1999): Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J. Clin. Psychopharmacol. 19: 427–434.Google Scholar
  10. Baumann P. (1996): Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31: 444–469.PubMedCrossRefGoogle Scholar
  11. Benkert O., Szegedi A., Kohnen R. (2000): Mirtazapine compared with paroxetine in major depression. J. Clin. Psychiatry 61: 656–663.CrossRefGoogle Scholar
  12. Berlin I., Lecrubier Y. (1996): Food and drug interactions with monoamine oxidase inhibitors: How safe are the newer agents? CNS Drugs 5: 403–413.CrossRefGoogle Scholar
  13. Blin O. (1999): A comparative review of new antipsychotics. Can. J. Psychiatry 44: 235–244.PubMedGoogle Scholar
  14. Bon S., Hartmann K., Kuhn M. (1999): Johanniskraut: Ein Enzyminduktor? Schweiz. Ap. Ztg. 16: 535–536.Google Scholar
  15. Braun M., Strasser R.H. (1997): Trizyklische Antidepressiva and kongestive Kardiomypathie. Der Internist 38: 1236–1238.PubMedGoogle Scholar
  16. Caley C.F., Weber S.S. (1995): Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann. Pharmacother. 29: 152–160.PubMedGoogle Scholar
  17. Carriere P., Bonhomme D., Lemperiere T. (2000): Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur. Psychiatry 15: 321–329.PubMedCrossRefGoogle Scholar
  18. Carter C.S., Mulsant B.H., Sweet R.A., Maxwell R.A., Coley K. et al. (1995): Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol. Bull. 31: 719–25.Google Scholar
  19. Chick J., Howlett H., Morgan M.Y., Ritson B. (2000): United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176–187.PubMedCrossRefGoogle Scholar
  20. Chouinard G., Jones B., Remington G., Bloom D., Addington D. et al. (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13: 25–40.PubMedCrossRefGoogle Scholar
  21. Colonna L., Saleem P., Dondey-Nouvel L., Rein W. (2000): Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int. Clin. Psychopharmacol. 15: 13–22.CrossRefGoogle Scholar
  22. Csernansky J.G., Mahmoud R., Brenner R. (2002): A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346: 16–22.PubMedCrossRefGoogle Scholar
  23. Dardennes R., Even C., Bange E., Heim A. (1995): Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders — a metaanalysis. Brit. J. Psychiat. 166: 378–381.PubMedCrossRefGoogle Scholar
  24. De Abajo F.J., Rodriguez L.A.G., Montero D. (1999): Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Brit. Med. J. 319: 1106–1109.PubMedCrossRefGoogle Scholar
  25. De Smet P.A.G.M., Touw D.J. (2000): Safety of St John’s wort (Hypericum perfora-turn). Lancet 355: 575–576.PubMedCrossRefGoogle Scholar
  26. Dettling M., Hellweg R., Cascorbi I., Deichle U., Weise L., Müller-Oerlinghausen B. (1999): Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine? Pharmacopsychiatry 32: 32: 110–112.PubMedCrossRefGoogle Scholar
  27. Di Carlo G., Borreli F., Ernst E., Izzo A.A. (2001): St John’s wort: Prozac from the plant kingdom. Trends Pharmacol. Sci. 22: 292–297.Google Scholar
  28. Dinan T.G. (2002): Lithium in bipolar mood disorder. Evidence suggests that lithium should still be first choice for prophylactic treatment. Brit. Med. J. 324: 988–989.CrossRefGoogle Scholar
  29. Donovan S., Clayton A., Beeharry M., Jones S., Kirk C., Waters K. et al. (2000): Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br. J. Psychiatry 177: 551–556.Google Scholar
  30. Duggan L., Fenton M., Dardennes R.M., El-Dosoky A., Indran S. (2000): Olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2: CD001359.PubMedGoogle Scholar
  31. Einarson T.R., Arikian S.R., Casciano J., Doyle J.J. (1999): Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin. Ther. 21: 296–308.PubMedCrossRefGoogle Scholar
  32. Eiliger T., Englert E., Freisleder F.J., Friedrich M., Gierow B. et al. (1994): Zur Behandlung schizophrener Psychosen des Kindes-and Jugendalters mit Clozapin (Leponex). Konsensuskonferenz vom 4. März 1994, Kinder and Jugendpsychiatrie. Z. Kinder-Jugendpsychiat. 22: 325–327.Google Scholar
  33. Elliger T.J., Trott G.E., Nissen G. (1990): Prevalence of psychotropic medication in childhood and adolescence in the Federal Republic of Germany. Pharmacopsychiatry 23: 38–44.PubMedCrossRefGoogle Scholar
  34. Ernst E. (2000): Second thoughts about safety of St. John’s wort. Lancet 354: 2014–2016.CrossRefGoogle Scholar
  35. Franchini L., Zanardi R., Gasperini M., Perez J., Smeraldi E. (1996): Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. J. Affect. Disord. 38: 67–69.PubMedCrossRefGoogle Scholar
  36. Frank E., Kupfer D.J., Perel J.M. (1990): Three-years outcomes for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 47: 1093–1099.PubMedCrossRefGoogle Scholar
  37. Gelenberg A.J., Lydiard R. B., Rudolph R.L., Aguiar L., Haskins J.T., Salinas E. (2000): Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283: 3082–3088.PubMedCrossRefGoogle Scholar
  38. Goldstein J.M. (2000): The new generation of antipsychotic drugs: how atypical are they ? Int. J. Neuropsychopharmacol. 3: 339–349.PubMedCrossRefGoogle Scholar
  39. Goodnick P.J., Barrios C.A. (2001): Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin. Pharmacother. 2: 667–680.PubMedCrossRefGoogle Scholar
  40. Greil W., Ludwig-Mayerhofer W., Erazo N., Engel R.R., Czernik A. et al. (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J. Affect. Disord. 40: 179–190.Google Scholar
  41. Guelfi J.D., Ansseau M., Timmerman L., Korsgaard S. (2001): Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J. Clin. Psychopharmacol. 21: 425–431.PubMedCrossRefGoogle Scholar
  42. Guzelcan Y., Scholte W.F., Assies J., Becker H.E. (2001): Mania during the use of a combination preparation with St. John’s wort (Hypericum perforatum). Ned. Tijdschr. Geneeskd. 6: 1943–1945.Google Scholar
  43. Hypericum Depression Trial Study Group (2002): Effect of Hypericum perforatum (St John’s Wort) in major depressive disorder. JAMA 287: 1807–1814.CrossRefGoogle Scholar
  44. Johne A., Brockmöller J., Bauer S., Maurer A., Langheinrich M., Roots I. (1999): Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66: 338–345.CrossRefGoogle Scholar
  45. Johne A., Schmider J., Brockmöller J., Stadelmann A.M., Stormer E., Bauer S. et al. (2002): Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J. Clin. Psychopharmacol. 22: 46–54.Google Scholar
  46. Kane J., Honigfeld G., Singer J., Meltzer H. (1988): Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45: 789–796.PubMedCrossRefGoogle Scholar
  47. Kappler J., Menges C., Ferbert A., Ebel H. (1994): Schwere „Spät“dystonie nach „Neuroleptanxiolyse” mit Fluspirilen. Nervenarzt 65: 66–68.PubMedGoogle Scholar
  48. Kasper S. (1996): Mirtazapin. Klinisches Profil eines noradrenalin-and serotoninspezifischen Antidepressivums. Arzneimitteltherapie 14 (9): 257–259.Google Scholar
  49. Kimko H.C., Cross J.T., Abernethy D.R. (1999): Pharmacokinetics and clinical effectiveness of methylphenidate. Clin. Pharmakokinet. 37: 457–470.CrossRefGoogle Scholar
  50. Kornhuber J. (1994): Potentielle Antipsychotica mit neuartigen Wirkmechanismen. In: Riederer P., Laux G., Pöldinger W. (Hrsg.): Neuropsychopharmaka, Bd. 4: Neuroleptica. Springer-Verlag, Wien New York, S. 185–196.Google Scholar
  51. Laakmann G., Schüle C., Baghai T., Kieser M. (1998): St. John’s wort in mild to moderate depression: The relevance of hyperforin for clinical efficacy. Pharmacopsychiatry 31 (Suppl.): 54–59.PubMedCrossRefGoogle Scholar
  52. Laties A.M. (2002): Quetiapine and cataracts. Am. J. Psychiatry 159: 322–323.PubMedCrossRefGoogle Scholar
  53. Laux G. (2001): Cost benefit analysis of newer vs. older antidepressants. Pharmacopsychiatry 34: 1–5.PubMedCrossRefGoogle Scholar
  54. Laux G., Volz H.-P., Möller H.-J. (1995): Newer and older monoamine oxidase inhibitors. CNS Drugs 3: 145–158.CrossRefGoogle Scholar
  55. Lantz M.S., Buchalter E., Giambanco V. (1999): St. John’s wort and antidepressant drug interactions in the elderly. J. Geriatr. Psychiatry Neurol. 12: 7–10.Google Scholar
  56. Lehmann K., Müller-Oerlinghausen B. (1993): Kosten-/Nutzen-Kalkulation der Lithium-Langzeit-Prophylaxe. Klin. Pharmakol. Aktuell 4: 68–70.Google Scholar
  57. Lepine J.P., Gastpar M., Mendlewicz J., Tylee A. (1997): Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol. 12: 19–29.PubMedCrossRefGoogle Scholar
  58. Lesch O.M., Riegler A., Gutierrez K., Hertling I., Ramskogler K., Semler B. et al. (2001) The European acamprosate trials. Conclusions for research and therapy. J. Biomed. Sci. 8: 89–95.Google Scholar
  59. Linde K., Mulrow C.D. (2000): St. John’s wort for depression. Cochrane Database Syst. Rev. 2000 (2): CD000448.Google Scholar
  60. Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., Melchart D. (1996): St John’s wort for depression — an overview and meta-analysis of randomised clinical trials. Brit. Med. J. 313: 253–258.Google Scholar
  61. Linden M., Gothe, H. (1993): Benzodiazepine substitution in medical practice. Analysis of pharmacoepidemiological data based on expert interviews. Pharmacopsychiatry 26: 107–113.Google Scholar
  62. Macritchie K.A.N., Geddes M.R., Scott J., Haslam D.R.S., Goodwin G.M. (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software.Google Scholar
  63. Marder S.R., Meibach R.C. (1994): Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151: 825–835.Google Scholar
  64. Möller H.-J. (1999): Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 249 (Suppl. 4): 99–107.PubMedCrossRefGoogle Scholar
  65. Möller H.-J., Volz H.P., Reimann I.W., Stoll K.D. (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J. Clin. Psychopharmacol. 21: 59–65.Google Scholar
  66. Moncrieff J. (2001): Are antidepressants overrated? A review of methodological problems in antidepressant trials. J. Nerv. Ment. Dis. 189: 288–295.PubMedCrossRefGoogle Scholar
  67. Montgomery S.A., Roberts A., Patel A.G. (1994): Placebo-controlled efficacy of antidepressants in continuation treatment. Int. Clin. Psychopharmacology 9: 49–53.CrossRefGoogle Scholar
  68. Moore L. B., Goodwin B., Jones S.A., Wisely G. B., Serabjit-Singh C.J., Willson T.M. et al. (2000): St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA 97: 7500–7502.Google Scholar
  69. Moses E.L., Mallinger A.G. (2000): St. John’s wort: three cases of possible mania induction. J. Clin. Psychopharmacol. 20: 115–117.Google Scholar
  70. MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiat. 56: 1073–1086.CrossRefGoogle Scholar
  71. Müller-Oerlinghausen B. (2001): Abhängigkeit und Mißbrauch von Substanzen. Dtsch. Ärztebl. 98: A1625–A1627.Google Scholar
  72. Müller-Oerlinghausen B., Berghöfer A. (1999): Antidepressants and suicidal risk. J. Clin. Psychiatry 60 (suppl. 2): S94–S99.Google Scholar
  73. Müller-Oerlinghausen B., Berghöfer A., Bauer M. (2002): Bipolar disorder. Lancet 359: 241–247.PubMedCrossRefGoogle Scholar
  74. Müller-Oerlinghausen B., Greil W., Berghöfer A. (Hrsg.) (1997): Die Lithiumtherapie. Nutzen Risiken Alternativen. Springer-Verlag, Berlin Heidelberg New York.Google Scholar
  75. Nierenberg A.A., Burt T., Matthews J., Weiss A.P. (1999): Mania associated with St. John’s wort. Biol. Psychiatry 46: 1707–1708.Google Scholar
  76. Olfson M., Marcus S.C., Pincus H.A., Zito J.M., Thompson J.W., Zarin D.A. (1998): Antidepressant prescribing practices of outpatient psychiatrists. Arch. Gen. Psychiatry 55: 310–316.Google Scholar
  77. Parker V., Wong A.H., Boon H.S., Seeman M.V. (2001): Adverse reactions to St John’s wort. Can. J. Psychiatry 46: 77–79.PubMedGoogle Scholar
  78. Philipp M., Kohnen R., Hiller K.O. (1999): Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Brit. Med. J. 319: 1534–1538.Google Scholar
  79. Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., Falloon J. (2000): Indinavir concentrations and St John’s wort. Lancet 355: 547–548.PubMedCrossRefGoogle Scholar
  80. Riederer P., Laux G., Pöldinger W. (Hrsg.) (1993): Neuropsychopharmaka Bd. 3 Antidepressiva and Phasenprophylaktika. Springer-Verlag, Wien New York.Google Scholar
  81. Rüther E., Ahrens B., Dieterle D., Erzgikeit A., Gaertner H.J. et al. (1995): Das AsoloSchema zur therapierelevanten multidimensionalen Klassifizierung der Antidepressiva. Psychopharmakotherapie 2: 158–164.Google Scholar
  82. Ruschitzka E, Meier P.J., Turina M., Lüscher T.F., Noll G. (2000): Acute heart transplant rejection due to Saint John’s wort. Lancet 355: 548–549.PubMedCrossRefGoogle Scholar
  83. Safer D.J. (2000) Are stimulants overprescribed for youths with ADHD ? Ann. Clin. Psychiatry 12: 55–62.PubMedCrossRefGoogle Scholar
  84. Schnyder U., Koller-Leiser A. (1996): A double-blind, multicentre study of paroxetine and maprotiline in major depression. Can. J. Psychiatry 41: 239–44.Google Scholar
  85. Schou M. (1998): Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 31: 210–215.PubMedCrossRefGoogle Scholar
  86. Schrader E. (2000): Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int. Clin. Psychopharmacol. 15: 61–68.PubMedCrossRefGoogle Scholar
  87. Schubert I., Lehmkuhl G., Spengler A., Döpfner M., von Ferber L. (2001): Methylphenidat bei hyperkinetischen Störungen. Dtsch. Ärztebl. 98: A541–A544.Google Scholar
  88. Schulz V., Hänsel R. (Hrsg.) (1996): Rationale Phytotherapie. Ratgeber für die ärztliche Praxis. Springer-Verlag, Berlin Heidelberg New York.Google Scholar
  89. Shelton R.C., Keller M. B., Gelenberg A., Dunner D.L., Hirschfeld R., Thase M.E. et al. (2001): Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA 285: 1978–1986.PubMedCrossRefGoogle Scholar
  90. Snow V, Lascher S., Mottur-Pilson C., for the American College of Physicians — American Society of Internal Medicine (2000): Clinical guideline I. Pharmacological treatment of acute major depression and dysthymia. Ann. Int. Med. 132: 739–742.Google Scholar
  91. Stip E. (2000): Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J. Psychiatry Neurosci. 25: 137–153.PubMedGoogle Scholar
  92. Sugimoto K., Ohmori M., Tsuruoka S., Nishiki K., Kawaguchi A., Harada K. et al. (2001): Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin. Pharmacol. Ther. 70: 518–524.Google Scholar
  93. Swift R.M. (1999): Drug therapy for alcohol dependence. N. Engl. J. Med. 340: 1482–1490.PubMedCrossRefGoogle Scholar
  94. Taylor D.M., McAskill R. (2000): Atypical antipsychotics and weight gain — a systematic review. Acta Psychiatr. Scand. 101: 416–432.PubMedCrossRefGoogle Scholar
  95. Tempesta E., Janiri L., Bignamini A., Chabac S., Potgieter A. (2000): Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35: 202–209.PubMedCrossRefGoogle Scholar
  96. Thase M.E., Nierenberg A.A., Keller M. B., Panagides J. (2001): Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J. Clin. Psychiatry 62: 782–788.Google Scholar
  97. Trindade E., Menon D., Topfer L.A., Coloma C. (1998): Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Canad. Med. Ass. J. 159: 1245–1252.Google Scholar
  98. Volz H.P., Hänsel R. (1994): Kava-Kava and Kavain in der Psychopharmakotherapie. Psychopharmakotherapie 1: 33–39.Google Scholar
  99. Volz H.P., Gleiter C.H., Möller H.J. (1996): Monoaminoxidasehemmer in der Psychiatrie. Nervenarzt 67: 339–347.PubMedGoogle Scholar
  100. Volz H., Möller H., Reimann I., Stoll K. (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur. Neuropsychopharmacol. 10: 211–217.PubMedCrossRefGoogle Scholar
  101. Walsh B.T., Seidman S.N., Sysko R., Gould M. (2002): Placebo response in studies of major depression. Variable, substantial and growing. JAMA 287: 1840–1847.PubMedCrossRefGoogle Scholar
  102. Wang Z., Hamman M.A., Huang S.M., Lesko L.J., Hall S.D. (2002): Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin. Pharmacol. Ther. 71: 414–420.PubMedCrossRefGoogle Scholar
  103. Wetterling T. (2001): Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. 24: 59–73.PubMedCrossRefGoogle Scholar
  104. Williams J.W.Jr., Mulrow C.D., Chiquette E., Hitchcock Noël P., Aguilar C., Cornell J. (2000): Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann. Intern. Med. 132: 743–756.Google Scholar
  105. Woelk H. (2000): Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. Brit. Med. J. 321: 536–539.PubMedCrossRefGoogle Scholar
  106. Woods J.H., Winger G. (1995): Current benzodiazepine issues. Psychopharmacology 118: 107–115.PubMedCrossRefGoogle Scholar
  107. Yue Q.-Y., Bergquist C., Gerdén B. (2000): Safety of St John’s wort (Hypericum perforatum). Lancet 355: 576–577.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Martin J. Lohse
  • Anna Lorenzen
  • Bruno Müller-Oerlinghausen

There are no affiliations available

Personalised recommendations